Firefly Bio Acquired by Johnson & Johnson | Healthcare M&A Deal

Johnson & Johnson has acquired Firefly Bio, a oncology business in New Jersey, for $1B. Firefly Bio develops oncology-focused therapeutics and research capabilities that can strengthen Johnson & Johnson’s cancer pipeline. The Johnson & Johnson acquisitions strategy targets growth in healthcare M&A and supports expansion of oncology programs based in NJ. This add on acquisition is a strategic acquisition by a corporate buyer, with the Firefly Bio acquisition positioned as an add on acquisition to complement existing oncology assets. The deal is announced and structured as a strategic acquisition, with closing timing and deal terms not specified.